Biolab acquires Actavis Brasil from Teva

Biolab has acquired Actavis Brasil from Teva, gaining a factory in Rio de Janeiro and a portfolio of 30 products. The deal was concluded in late June 2018; the value is undisclosed but estimated at R$ 40-60 million.

“We're going to play in generics, but without giving up Biolab's DNA, which is innovation.”biolabeco.com.br

• 1 source
• biolabeco.com.brBiolab enters generics and evaluates purchase in Canada - Biolab & CoJul 4, 2018

Summarized from public sources; check the original articles before acting on it.